Skip to main content

Table 1 Characteristics of included studies

From: Efficacy of convalescent plasma for the treatment of severe influenza

NO. Author Journal, years Study design Multi-center Population Dose Treatment (n) Control (n) Outcomes
1 Hung, et al. [18] CHEST, 2013 RCT, H-IVIG vs. normal IV immunoglobulin (IVIG) Yes Patients with severe H1N1 infection 0.4 g/kg 17 17 H-IVIG was associated with a lower viral load and reduced mortality
2 Group IFIPS [21] The Journal of Infectious Diseases, 2016 RCT, H-IVIG vs. placebo Yes Patients with influenza A or B 0.25 g/kg 16 15 H-IVIG administration significantly increases HAI titer levels among patients with influenza
3 Davey Jr., et al. [17] Lancet Respir Med, 2019 RCT, H-IVIG vs. placebo Yes Patients with influenza A or B infection 0.25 g/kg 156 152 H-IVIG was not superior to placebo for adults hospitalized with influenza infection
4 Beigel et al. [22] Lancet Respir Med, 2017 RCT, immune plasma vs. standard care Yes Patients with severe influenza A or B HAI titers ≥ 1:80 42 45 Immune plasma provided support for a possible benefit of severe influenza
5 Beigel et al. [16] Lancet Respir Med, 2019 RCT, high-titer anti-influenza plasma (≥ 1:80) vs. low-titer (≤ 1:10) Yes Patients with influenza A HAI titers ≥ 1:80 91 47 High-titer anti-influenza plasma conferred no significant benefit over non-immune plasma